DrugId:  1
1. Name:  Nagrestipen
2. Groups:  Investigational
3. Description:  Nagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.
4. Indication:  Not Available
DrugId:  2
1. Name:  Mubritinib
2. Groups:  Investigational
3. Description:  Mubritinib has been used in trials studying the treatment of Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm.
4. Indication:  Not Available
DrugId:  3
1. Name:  MLN8054
2. Groups:  Investigational
3. Description:  MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.
4. Indication:  Not Available
DrugId:  4
1. Name:  Demcizumab
2. Groups:  Investigational
3. Description:  Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
4. Indication:  Not Available
DrugId:  5
1. Name:  GSK-2636771
2. Groups:  Investigational
3. Description:  GSK2636771 has been used in trials studying the treatment of CANCER, LYMPHOMA, Solid Neoplasm, Recurrent Solid Neoplasm, and Advanced Malignant Neoplasm, among others.
4. Indication:  Not Available
DrugId:  6
1. Name:  Berzosertib
2. Groups:  Investigational
3. Description:  Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  Polihexanide
2. Groups:  Approved, Investigational
3. Description:  Polihexanide has been used in trials studying the treatment, prevention, and supportive care of Caries, Neoplasm, Skin Diseases, Nail Diseases, and Dental Plaque, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  Adecatumumab
2. Groups:  Investigational
3. Description:  Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
4. Indication:  Investigated for use/treatment in breast cancer and prostate cancer.
DrugId:  9
1. Name:  Motolimod
2. Groups:  Investigational
3. Description:  Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  Ceramide 3
2. Groups:  Approved
3. Description:  Ceramide 3 is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3 consists of a phytosphingosine backbone N-acylated with a saturated fatty acid (stearic acid) [2]. It is widely used as a moisturizer in various cosmetic and personal products. Together with ceramide 1, they synergistically improve the skin barrier function in humans [1, 2].
4. Indication:  Not Available
DrugId:  11
1. Name:  Isoxaflutole
2. Groups:  Approved, Investigational
3. Description:  Balance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
4. Indication:  Not Available
DrugId:  12
1. Name:  Diphencyprone
2. Groups:  Investigational
3. Description:  Diphencyprone has been used in trials studying the treatment and basic science of Melanoma, Ultraviolet Rays, Immunosuppression, Neoplasm Metastasis, and Hypersensitivity, Delayed, among others.
4. Indication:  Not Available
DrugId:  13
1. Name:  SAR-405838
2. Groups:  Investigational
3. Description:  SAR405838 has been used in trials studying the treatment of Neoplasm Malignant.
4. Indication:  Not Available
DrugId:  14
1. Name:  ZD-6126
2. Groups:  Investigational
3. Description:  ZD6126 has been used in trials studying the treatment of Kidney Neoplasms, Colorectal Neoplasms, Metastases, Neoplasm, and Carcinoma, Renal Cell.
4. Indication:  Not Available
DrugId:  15
1. Name:  Prexasertib
2. Groups:  Investigational
3. Description:  Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, BREAST CANCER, and Ovarian Cancer, among others.
4. Indication:  Not Available
DrugId:  16
1. Name:  Perfosfamide
2. Groups:  Investigational
3. Description:  Perfosfamide has been used in trials studying the treatment of Lymphoma, Neuroblastoma, and Multiple Myeloma and Plasma Cell Neoplasm.
4. Indication:  Not Available
DrugId:  17
1. Name:  Halofuginone
2. Groups:  Investigational, Vet approved
3. Description:  Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.
4. Indication:  For the treatment of scleroderma, cancer, and restenosis.
DrugId:  18
1. Name:  LY-3023414
2. Groups:  Investigational
3. Description:  LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
4. Indication:  Not Available
DrugId:  19
1. Name:  LY-2584702
2. Groups:  Investigational
3. Description:  LY2584702 has been used in trials studying the treatment of Cancer, Advanced Cancer, Renal Cell Carcinoma, Metastases, Neoplasm, and Neuroendocrine Tumors, among others.
4. Indication:  Not Available
DrugId:  20
1. Name:  Ilorasertib
2. Groups:  Investigational
3. Description:  Ilorasertib has been used in trials studying the treatment of Myelodysplasia, Solid Neoplasm, Advanced Cancers, Advanced Solid Tumors, and Acute Myelogenous Leukemia, among others.
4. Indication:  Not Available
DrugId:  21
1. Name:  Mafosfamide
2. Groups:  Investigational
3. Description:  Mafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.
4. Indication:  Not Available
DrugId:  22
1. Name:  CP-724714
2. Groups:  Investigational
3. Description:  CP-724,714 has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasm Metastasis.
4. Indication:  Not Available
DrugId:  23
1. Name:  Taselisib
2. Groups:  Investigational
3. Description:  Taselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.
4. Indication:  Not Available
DrugId:  24
1. Name:  Becaplermin
2. Groups:  Approved, Investigational
3. Description:  Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.
4. Indication:  For topical treatment of skin ulcers (from diabetes)
DrugId:  25
1. Name:  Gedatolisib
2. Groups:  Investigational
3. Description:  Gedatolisib has been used in trials studying the basic science and treatment of Neoplasm, Ovary Cancer, Breast Cancer, Advanced Cancer, and Endometrial Cancer, among others.
4. Indication:  Not Available
